You are here: Home / Documents

Documents

Immune tolerance induction in ERT to treat infantile-onset Pompe disease: Current practice
FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Agenda
fda-agenda
Non-Cytotoxic, Non-Immunosuppressing Approach to Tolerance Induction During ERT Treatment
Pharmacologic Approaches for Immune Tolerance
Assessing immunogenicity during clinical development: – An Industry Perspective
Anti-Drug Antibodies in Patients with Lysosomal Storage Disorders (LSD’s): Clinician’s Perspective
Immune Responses and the Role of Immune Tolerance Induction in Enzyme Replacement Therapies for Lysosomal Storage Diseases: the FDA Perspective
Role of Immune Tolerance Induction Public Workshop
Thank You Letter to Gov O'Malley for Passage of HB761
NORD URGES FDA TO CONSIDER RARE DISEASE TREATMENT IMPLICATIONS WHEN SETTING BIOLOGICS NAMING POLICY
In a letter submitted today to FDA, NORD urged Commissioner Hamburg to give serious consideration to the concerns of the rare disease community when setting policy regarding official names for biologics, including biosimilars.
Northern California Autoinflammatory Picnic Jul 26, 2014 from 12:00 PM to 03:00 PM Howarth Park Lower Oak Picnic Areas 1 & 2 630 Summerfield Rd. Santa Rosa, CA 95405 ,
The Autoinflammatory Alliance is hosting a picnic on July 26th in Santa Rosa, CA, for patients and families affected by autoinflammatory disease.
carousel-cbi
biosimilars-2014
cures-comments
amicus-2007
lymphedema
jmml
joe-pnh
woodcock

WHAT IS NORD?

The National Organization for Rare Disorders (NORD) provides advocacy, education and other services to improve the lives of all people affected by rare diseases. More >

NORD Get our latest e-news

 
Copyright ©2014 NORD - National Organization for Rare Disorders, Inc. All rights reserved.
The following trademarks/registered service marks are owned by NORD: NORD, National Organization for Rare Disorders, the NORD logo, RareConnect. .